Search

Displaying results 1351 - 1360 of 6834 in total
  1. Drug

    Larotrectinib

    go.drugbank.com/drugs/DB14723
    ApprovedInvestigational

    [L49821] Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition … [L49821] Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors.

  2. Drug

    Isoeugenol

    go.drugbank.com/drugs/DB14188
    Approved

    It is also a significant dermatologic sensitizer and allergen, and as a result has been restricted to 200 p.p.m. since 1998 according to guidelines issued by the fragrance industry [A34278]. … Allergic reactivity to Isoeugenol may be identified with a patch test.

  3. Drug

    Amikacin

    go.drugbank.com/drugs/DB00479
    ApprovedInvestigationalVet approved

    of patients with the disease who do not respond to traditional treatment. … [F1949] In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population

    Synonyms: O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6))-N(SUP 3)-(4-AMINO-L-2-HYDROXYBUTYRYL)-2-DEOXY-L-STREPTAMINE, D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4))-N(SUP 1)-(4-AMINO-2-HYDROXY-1-OXOBUTYL)-2-DEOXY-, (S)-
  4. Drug

    Inosine

    go.drugbank.com/drugs/DB04335
    Approved

    A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. … It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules.

  5. Drug

    Technetium Tc-99m succimer

    go.drugbank.com/drugs/DB09436
    Approved

    It works by binding to the cortical region of the kidneys. Technetium Tc-99m succimer is used with gamma scintigraphy or single-photon emission computed tomography (SPECT). … [L40558] The use of technetium Tc-99m succimer for the detection of kidney cortical defects was first approved by the FDA on February 23, 2022, under the market name NephroScan.[L40573]

    Synonyms: (99m)Tc-DMSA, Technetium tc 99m succimer
  6. Drug

    Favipiravir

    go.drugbank.com/drugs/DB12466
    ApprovedInvestigational

    influenza strains that are resistant to neuramidase inhibitors. … Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza.

  7. Drug

    Bacitracin

    go.drugbank.com/drugs/DB00626
    ApprovedInvestigationalVet approved

    Bacitracin is a combination of at least 9 bacitracins. 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named M...

    Mixtures: Neosporin Plus Pain Relief Neo to Go, Bus and Classroom Yellow
  8. Drug

    Ubidecarenone

    go.drugbank.com/drugs/DB09270
    ApprovedInvestigationalNutraceutical

    From its name (Q10), the Q refers to the constitutive quinone group, and 10 is related to the number of isoprenyl subunits in its tail. … [L1062] Ubidecarenone is sold as a dietary supplement and is not FDA approved as a drug - it is not meant to treat, cure or prevent any disease.

    Mixtures: Shine CO-Q Plus, Co-q10 M.R.B. 60mgSynonyms: Co Enzyme Q10, Co-Enzyme Q10
  9. Drug

    Atoltivimab

    go.drugbank.com/drugs/DB15898
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high

  10. Drug

    Phenoxypropazine

    go.drugbank.com/drugs/DB09251
    ApprovedWithdrawn

    It was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential. … Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the _hydrazine_ chemical class.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome